AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma

AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma

Shots:

  • The P-III study results involves assessing of Depatux-M (depatuxizumab mafodotin, ABT-414) + SOC therapy of radiation + temozolomide vs PBO + SOC in 639 patients with newly diagnosed EGFR-amplified GBM
  • AbbVie has halted the enrollment of patients in all ongoing studies of Depatux-M due to its inability to meet 1EP, demonstrated no survival benefits & no new safety is observed. IMDC has also recommended for the termination of INTELLANCE-1 study due to lack of survival benefits
  • Depatux-M (depatuxizumab mafodotin) is an ADC targeting EGFR-amplification, evaluated to treat glioblastoma under the collaboration of AbbVie & RTOG foundation

Click here to read full press release/ article | Ref: AbbVie | Image: Punktlandung